CN107058484A - It is a kind of to detect T cell and the primer combination in B cell immune group storehouse and kit simultaneously applied to high-flux sequence - Google Patents

It is a kind of to detect T cell and the primer combination in B cell immune group storehouse and kit simultaneously applied to high-flux sequence Download PDF

Info

Publication number
CN107058484A
CN107058484A CN201611217595.1A CN201611217595A CN107058484A CN 107058484 A CN107058484 A CN 107058484A CN 201611217595 A CN201611217595 A CN 201611217595A CN 107058484 A CN107058484 A CN 107058484A
Authority
CN
China
Prior art keywords
primer
tcr
cell
bcr
areas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201611217595.1A
Other languages
Chinese (zh)
Other versions
CN107058484B (en
Inventor
孙涛
刘潇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Immuquad Biotechnologies LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201611217595.1A priority Critical patent/CN107058484B/en
Publication of CN107058484A publication Critical patent/CN107058484A/en
Application granted granted Critical
Publication of CN107058484B publication Critical patent/CN107058484B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1093General methods of preparing gene libraries, not provided for in other subgroups
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06Biochemical methods, e.g. using enzymes or whole viable microorganisms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention belongs to molecular Biological Detection field, it is more particularly to a kind of to detect T cell (TCR) and the primer combination in B cell (BCR) immune group storehouse and kit simultaneously applied to high-flux sequence, the primer combination includes the Oligo of XCR 3 ' (dT) primer, the Oligo joints of XCR 5 ', the end connector primers of XCR 5 ', TCR alpha chain C areas primer, TCR beta chain C areas primer, IgA, IgG and IgM in BCR Heavy chain C areas primer, Kappa and Lambda in BCR Light chain C areas primer, and label upstream and downstream primer;The kit includes primer combination as claimed in claim 1 or 2.Obtain TCR in lymphocyte(Alpha chains or Beta chains)And BCR(Heavy chains or Light chains)Gene order total length information.

Description

It is a kind of to detect drawing for T cell and B cell immune group storehouse simultaneously applied to high-flux sequence Thing is combined and kit
Technical field
The invention belongs to biology field, more particularly to a kind of high-flux sequence that is applied to detects T cell simultaneously Primer combination and kit with B cell immune group storehouse.
Background technology
Substantial amounts of V (variable region) on T, B cell locus, D (variable region), J (bonding pad) genetic fragments T, B cell by Each species diversity restructuring can be produced in the formation of body.It is unique that the restructuring of this V-D-J genes imparts each T, B cell oneself T, B-cell receptor (TCR, BCR) so that each TCR and BCR sequence can effectively turn into T, a B cell gram Grand unique biomarker.
Because the maximum feature of TCR and BCR genes is the random restructuring of V, D, J genetic fragment, so, for unknown gene Sequence the, it is difficult to 5 ' terminal sequences that a sense primer is used to recognize TCR, BCR gene be designed, so can not also utilize round pcr Expand TCR, BCR gene and sequencing.
And another TCR sequence measurement, the method for Multiplex PCR, the partial sequence letter in tcr gene can only be sequenced Breath, so that sequencing gene information is imperfect.In addition, the primer of Multiplex PCR method is according to known V, the design of J genes , this sequencing result is confined to the known of wild type.But in cancer patient, the gene mutation of cancer cell is very normal See, if the BCR or TCR of leukaemia cancer cell generate mutation, then the primer of known array is possible to None- identified Gene after mutation, for testing result, is easy for causing false negative.Also, the immune group storehouse sequencing side of Multiplex PCR Method, is only sequenced to TCR or BCR, has just needed tens pairs of primer, huge if detection TCR and BCR simultaneously Primer quantity the efficiency and specificity of whole PCR amplification can be allowed to become very poor.
So, it can detect TCR and BCR simultaneously in an experimental implementation there is presently no a technology, utilize us Method (single pair of primer method) can detect the TCR and BCR of multiple samples simultaneously, save experimental period and reagent, cost of labor. The technology can be applied in the research of immunogene group, can not only detect the minimal residual after lymphoid malignancy treatment Disease, additionally it is possible to judge the immunologic reconstitution after HSC transplanting, food hypersenstivity, the detection of immunity disease etc..
The content of the invention
In order to solve the above technical problems, the present invention, which provides a kind of high-flux sequence that is applied to, detects that T cell and B are thin simultaneously The primer combination in born of the same parents' immune group storehouse and kit, φt cell receptor and B-cell receptor library structure are built based on high-flux sequence simultaneously The cDNA joints and single pair of primer built, by the anti-sense primer of the sense primer from joint to C areas, while obtaining TCR and BCR bases Because of the total length information of sequence.
Primer combination can effectively expand the complete sequence of tcr gene in the present invention, bis- generations of TCR sequencing library is built efficiency Efficiently.Kit has provided the user simple and convenient application method, stabilised efficiency.TCR and BCR can be completed simultaneously builds storehouse, Build object and the combination (different chains) in storehouse.
Solve a kind of of above technical problem and detect T cell and B cell immune group storehouse simultaneously applied to high-flux sequence Primer is combined, it is characterised in that:The primer combination includes the Oligo of XCR 3 ' (dT) primer, the Oligo joints of XCR 5 ', XCR5 ' IgA, IgG in end connector primer, TCR-alpha chain C areas primer, TCR-beta chain C areas primer, BCR-Heavy chain C areas primer And Kappa and Lambda in IgM, BCR-Light chain C areas primer, and label upstream and downstream primer;Every kind of primer sequence is such as Under:
The Oligo of XCR 3 ' (dT) primer:5’TTTTTTTTTTTTTTTTTTTTGA 3’;
The Oligo joints of XCR 5 ':5’ATGCATCGGATCTTCAGCATGAACTTrGrGrG 3’;
The end connector primers of XCR 5 ':
5’GTCTCGTGGGCTGGGCGATGTGTATGAGAGACAGCATGCATCGGATCTTCAGCATGA 3’;
TCR-alpha chain C areas primer:
5’TCGTCGCCAGCGTCGGAAGTGTATAAGAGACAGTCTCAGCTGGTACATATCGATGTCAGGGT 3’;
TCR-beta chain C areas primer:
5’TCGTCGCCAGCGTCGGAAGTGTATAAGAGACAGTCGCAGCGTCAGATGTGTATAAGAGACAG 3’;
BCR-Heavy chain C areas primer:
IgA:5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTAGGCTCCTGGGTTCCGAAGCC 3’;
IgG:5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTAGCGCCTGAGAAGGACGACAC 3’;
IgM:5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTAGGGGAATTCTTCTGGGAGAC 3’;
BCR-Light chain C areas primer:
Kappa:
5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTACCTTCCACTCTATATTGGCCTC 3’;
Lambda:
5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTAGCCACTGTATCCGCTCCCGGG 3’;
Label sense primer:5’CAAGCAGAAGACGGCATACGAGAT[index1]GTCTCGTGGGCTGG 3’;
Label TCR anti-sense primers:5’AATGATACGGCGACCACCGAGATCTACAC[index2]TCGTCGCCAGCGTC
3’;
Label B CR anti-sense primers:5’AATGATACGGCGACCACCGAGATCTACAC[index3]TACGCGATATCGCT
3’;
Wherein, the index1 be ATCTATCG, TCAGGTGA, CACTAGTT, GAATTGCC, ATGTACAA, One kind in GATTCAGT, CTGTTCGT or TATACGGC;Index2 be TAGCTACT, ATTATAGC, CCCGTACT, One kind in GGGTATAA, AGCAGGTG, TATACGTA, CACCTAGT or GTTGCTAC;
Index3 be TAATCGCT, ATATTACC, CCTATACT, GGATGAAA, AGTCTTTG, TAGTGGTA, One kind in CACGATGT or GTATGAAC;
A kind of kit for detecting T cell and B cell immune group storehouse simultaneously applied to high-flux sequence in the present invention, its It is characterised by:The kit includes primer combination as claimed in claim 1 or 2.
Kit described in prioritization scheme in the present invention also includes PCR buffer solutions, Q5High-Fidelity 2X Master Mix, remove nuclease water, AMPure XP Beads and 70% ethanol.
In further prioritization scheme, the kit includes:
(1) PCR buffer solutions:9.5μL;
(2) positive control RNA (1 μ g/ μ l):10μL;
(3) the 10 μM of Oligo of TCR 3 ' (dT) primers:1.1μL;
(4) 10 μM of end connector primers of TCR 5 ':2.2μL;
(5) 10 μM of TCR C area's primers and 10 μM of BCR C areas primers:Each 1.1 μ L;
(6)Q5High-Fidelity 2X Master Mix:55μL;
(7) 10 μM of label sense primers:2.2μL;
(8) 10 μM of TCR labels anti-sense primers and 10 μM of BCR label anti-sense primers:Each 1.1 μ L;
(9) nuclease water is removed:105μL;
(10)AMPure XP Beads:88μL;
(11) 70% ethanol:165μL.
The PCR buffer solutions are made up of following system:
Kit be prepared as buy raw material, be then assembled into kit.According to required ratio, load test tube, encapsulation Into kit.Such as one kit, which can be divided into, makees 96 samples, 48 samples, two kinds of specifications etc..
Using the primer combination in the present invention and kit, so that high-flux sequence detects that T cell and B cell are immune simultaneously Group storehouse, detection method comprises the following steps:
(1) human blood sample 10mL is obtained in EDTA anticoagulant tubes;
(2) it is thin using lymphocyte separation medium Ficoll-1077 (Sigma Co., USA #10771) progress peripheral blood mononuclears The separation of born of the same parents (PBMC);
The effect of lymphocyte separation medium is that lymphocyte can be separated in whole blood, because T cell detects for us Object, T cell belongs to one kind of lymphocyte, and the RNA that the cell mass after separation is obtained is to eliminate red blood cell, blood platelet etc. The RNA's of cell.So building the total serum IgE that storehouse uses, to include T cell RNA template purity higher.
(3) PBMC total serum IgE is extracted using Trizol method, agents useful for same is RNAzol RT (MRC companies of U.S. # RN190);
Trizol method extracts RNA, and step is as follows:
Harvesting, is transferred in 1.5ml centrifuge tubes, adds 1ml Trizol, mixes, is stored at room temperature 5min.
0.2ml chloroforms are added, 15s is vibrated, 2min is stood.
0.5ml isopropanols are added, liquid in pipe is gently mixed, 10min is stored at room temperature.
4 DEG C of centrifugations, 12000g × 10min abandons supernatant.
The ethanol of 1ml 75% is added, gently washing precipitation.4 DEG C of centrifugations, 7500g × 5min abandons supernatant.
Natural air drying, adds 50ul DEPC H2O dissolvings, obtains lymphocyte total serum IgE.
(4) RNA reverse transcriptions are into cDNA, and simultaneously in the ends of cDNA 5 ' addition joint, and 5 ' ends are drawn when being expanded with PCR later Thing is combined;
In reverse transcription, while adding joint, loss of the RNA during multistep reaction can be minimized.RNA is in operation Middle stability extreme difference, is very easy to degraded, and a small amount of step can reduce degraded to the full extent, can be used for while also saving The cDNA preparation times of amplification.
Joint is the nucleic acid linker at cDNA 5 ' ends, the Oligo joints of XCR 5 '.
(5)PCR1:Restructuring TCR and BCR is expanded by way of 1 sense primer, the anti-sense primer of 2 or more than 2 cDNA;
(6) PCR2 and purifying:The upper of Illumina high-flux sequence instrument is added for PCR1 products (the TCR sequences after amplification) Machine joint and label, while more upper machine gene dosage is expanded again for increase;After PCR reactions terminate, DNA is carried out using magnetic bead Purifying.
PCR primer is typically all containing excessive primer, Taq DNA enzymatics and dNTP.The presence of these compositions will be directly affected To processes such as follow-up library quality inspection, sequencing reactions, purifying can remove the accessory substance of these influence subsequent experimentals.Meanwhile, it is pure The process of change is also that the DNA fragmentation in the process of clip size screening, the present invention is in 700bp or so, using difference The magnetic bead of volume is mixed with PCR primer, and volume ratios different magnetic bead/DNA can adsorb different size of fragment, using above-mentioned Magnetic bead volume, can successfully remove machine text in mistake (error) fragment and primer dimer when PCR is expanded, the sequencing of let us There was only our sequencing target DNA fragments in storehouse so that sequencing result is more accurate, reduce error.
As shown in figure 3, being only found that the peak of a fragment by library quality inspection.
(7) high-flux sequence is carried out:The cDNA library of gained is sequenced by Illumina MiSeq platforms, is sequenced Pattern is PE300, and library denaturant concentration is 2nM, and upper machine concentration is 20pM, and passes through bioinformatic analysis high-flux sequence knot Really;
Up to a million s' obtained by the end connectors of XCR 5 ' of the present invention, PCR primer and sequencing library preparation method TCR and BCR sequences, the technology can be applied in the research of immunogene group, can not only detect that lymphoid malignancy is controlled Minimal residual disease after treatment, additionally it is possible to judge the immunologic reconstitution after HSC transplanting, food hypersenstivity, the detection of immunity disease etc..
In heretofore described step (4) each RNA sample is mixed according to following ratio:
Reagent volume 1X (μ L),
RNA 8,
The Oligo of TCR 3 ' (dT) primer (10 μM) 1,
Hatch in 72 DEG C 3 minutes, then 4 DEG C 1 minute.
PCR reaction buffers are prepared according to following ratio
PCR reactions caching liquid and RNA samples are mixed, cDNA reverse transcriptions are started according to following response procedures
42 DEG C 60 minutes
70 DEG C 10 minutes
4 DEG C permanent
After reaction terminates, so that it may obtain and with the addition of total cDNA (such as Fig. 1) of joint at 5 ' ends.
Comprised the following steps that in the step (5):Reaction system is prepared according to following ratio:
Reaction system is prepared according to above-mentioned reaction system, above-mentioned 5 sample reagent is mixed in PCR test tubes, mixes, centrifuge number Second, the liquid residue on tube wall is centrifuged in ttom of pipe.Holding test tubes start fortune in PCR amplification instrument according to above-mentioned response procedures OK.
The response procedures of PCR 1 are in the step (5):
95 DEG C 3 minutes;95 DEG C 30 seconds;65 DEG C 1 minute, 25 circulation;72 DEG C 1 minute;4 DEG C permanent.
Comprised the following steps that in the step (6):
Reaction system is prepared according to following ratio:
The response procedures of PCR 2 are in the step (6):
94 DEG C 3 minutes;94 DEG C 30 seconds;55 DEG C 30 seconds, 18 circulation;72 DEG C 20 minutes, 72 DEG C 1 minute, 4 DEG C are permanent.
Specific purification step is as follows in the step (6):
(1) 80 μ L AMPure XP Beads of addition enter PCR2 reaction products, mix.
(2) in incubation at room temperature 10 minutes.
C, magnetic bead-PCR2 product mixtures test tube is placed on magnetic frame, wait after all magnetic beads are adsorbed on magnetic frame, All supernatants are sucked with pipettor, are abandoned.
(3) the addition ethanol of 150 μ L 70% is hatched 30 seconds on magnetic bead, all supernatants is sucked with pipettor, is abandoned.
(4) the 4th step is repeated 2 times.
(5) test tube cap is opened, is waited 5 minutes, treats that magnetic bead is air-dried, is residued in without any ethanol in test tube.
(6) test tube is removed from magnetic frame, and adds 50 μ L and remove nuclease water, suspension magnetic bead is blown and beaten using pipettor.
(7) tube back magnetic frame, all magnetic beads are waited all to be adsorbed in after magnetic frame, transfer supernatant is in new test tube In.The PCR2 products after purifying are just contained in supernatant.
The present invention is based on high throughput sequencing technologies, and the library constructing method of single pair of primer is sequenced in TCR, by thin in acquisition T After born of the same parents RNA, RNA is being carried out to while cDNA reverse transcriptions, to cDNA 5 ' one joint of end addition, so that by known to this The joint design TCR amplification sense primers of sequence, then coordinate tcr gene 3 ' to hold C area's genes (constant region) design anti-sense primer, from And reach the purpose for expanding whole TCR sequences gene.
Therefore it provides a kind of φt cell receptor and B-cell receptor detection means of being built based on high throughput sequencing technologies is simultaneously It is very significant, it is effective to save experimental period and reagent, cost of labor.
The present invention provides the beneficial effect of the joint for building TCR and BCR libraries simultaneously based on high-flux sequence, primer and method It is really:Obtain people TCR (Alpha chains or Beta chains) and BCR (Heavy chains or Light chains) complete genome sequence simultaneously;
The present invention is complete by being carried out to people's TCR and BCR gene sequencing result simultaneously on the basis of high-flux sequence platform The bioinformatic analysis in face, obtains the gene Preference of TCR and BCR when VDJ is recombinated, and VDJ assortment of genes information is immunized Group clone's kind of information, immune group diversity information, all CDR1, CDR2, CDR3 of immune group nucleotide sequence and amino acid Abrupt information on sequence information, gene, etc..Exactly these factor quantity of formation are huge and immune group storehouse of wide variety.
Brief description of the drawings
RNA reverse transcription cDNA schematic diagrames in Fig. 1 present invention
Upper machine joint schematic diagram is sequenced to be expanded TCR and BCR cDNA using twice PCR in the present invention and being added in Fig. 2
Fig. 3 is sequencing library quality inspection result in the present invention.
Fig. 4 carries out bioinformatic analysis comparison for TCR sequencing results in the present invention, finds out the information (portion of every sequence Point)
Fig. 5 carries out bioinformatic analysis comparison for BCR sequencing results in the present invention, finds out the information (portion of every sequence Point)
Embodiment
With reference to embodiment, the present invention is described in further detail, and primer is by the U.S. The synthesis of Invitrogen companies:
Embodiment 1
Using in the present invention primer combination and kit carry out high-flux sequence detection so that simultaneously detection T cell by Body and B-cell receptor, specific steps comprise the following steps:
(1) human blood sample 10mL is obtained in EDTA anticoagulant tubes;
(2) peripheral blood mononuclear is carried out using lymphocyte separation medium Ficoll-1077 (Sigma Co., USA #10771) The separation of cell (PBMC);
(3) PBMC total serum IgE is extracted using Trizol method, agents useful for same is RNAzol RT (MRC companies of U.S. # RN190);
(4) utilize2.0Fluorometer (U.S. Thermo Fisher Scientific company # Q32866), coordinateRNA HS Assay Kit kits (U.S. Thermo Fisher Scientific company # Q32852 RNA concentration) is determined, reverse transcription RNA is subsequently used for;
(5) RNA reverse transcriptions are into cDNA, and 5 ' the end primer knots when the ends of cDNA 5 ' addition joint is expanded with PCR later Close, comprise the following steps that,
The reagent used:
The Oligo of XCR 3 ' (dT) primer (10 μM)
5X reverse transcription buffers (250mM Tris-HCl (pH 8.3), 375mM KCl, 15mM MgCl2)
Dithiothreitol (DTT), DTT (20mM) U.S. Thermo Scientific#R0861
DNTP Mix (10mM) U.S. Invitrogen#18427088
RNAse Out (40U/ μ L) U.S. Invitrogen#10777019
The Oligo of XCR 5 ' joints (10 μM)
Superscript II RT (200U/ μ L) U.S. Invitrogen#18064022
Each RNA sample is mixed according to following ratio:
Reagent Volume 1X (μ L)
RNA 8
The Oligo of XCR 3 ' (dT) primer (10 μM) 1
Hatch in 72 DEG C 3 minutes, then 4 DEG C 1 minute.
PCR reaction buffers are prepared according to following ratio
Reagent Volume 1X (μ L)
5X reverse transcription buffers 3.5
DTT(20mM) 1
dNTP(10mM) 1
RNAse Out 1
The Oligo of XCR 5 ' joints (10 μM) 1
Superscript II RT 1
PCR reactions caching liquid and RNA samples are mixed, RNA reverse transcriptions are started according to following response procedures
42 DEG C 60 minutes
70 DEG C 10 minutes
4 DEG C permanent
After reaction terminates, so that it may obtain and with the addition of total cDNA (such as Fig. 1) of joint at 5 ' ends
(6) PCR (PCR1).By way of " single pair of " primer, or by under 1 sense primer, 2 or more than 2 The mode of primer is swum, while expanding restructuring TCR and BCR cDNA, is comprised the following steps that:
The reagent used:
Q5High-Fidelity 2X Master Mix (U.S. NEB#M0492L)
The end connectors of XCR 5 ' primer (sense primer)
TCR C areas primer (anti-sense primer)
BCR C areas primer (anti-sense primer)
Remove nuclease water (U.S. Thermo Scientific AM9914G)
Reaction system is prepared according to following ratio:
The response procedures of PCR 1 are:
(7) PCR (PCR2).For PCR1 products (TCR and BCR sequences after amplification) addition Illumina high-flux sequences The upper machine joint and label of instrument, while more upper machine gene dosage is expanded again for increase.Comprise the following steps that:
The reagent used:
Q5High-Fidelity 2X Master Mix (U.S. NEB#M0492L)
Label sense primer
Label TCR anti-sense primers
Label B CR anti-sense primers
Remove nuclease water (U.S. Thermo Scientific AM9914G)
Reaction system is prepared according to following ratio:
The response procedures of PCR 2 are:
(8) PCR2 product purifications.After above-mentioned PCR reactions terminate, DNA purifying is carried out using magnetic bead, is comprised the following steps that:
The reagent used:
Agencourt AMPure XP Beads (U.S. Beckman#A63882)
Specific purification step is as follows:
1. adding 80 μ L AMPure XP Beads enters PCR2 reaction products, mix.
2. in incubation at room temperature 10 minutes.
3. magnetic bead-PCR2 product mixtures test tube is placed after on magnetic frame, waiting all magnetic beads to be adsorbed on magnetic frame, All supernatants are sucked with pipettor, are abandoned.
4. adding the ethanol of 150 μ L 75% on magnetic bead, hatch 30 seconds, all supernatants are sucked with pipettor, abandon.
5. repeat the 4th step 2 times.
6. opening test tube cap, wait 5 minutes, treat that magnetic bead is air-dried, residued in without any ethanol in test tube.
7. a test tube is removed from magnetic frame, and 50 μ L of addition remove nuclease water, utilize pipettor to blow and beat suspension magnetic bead.
8. a tube back magnetic frame, waits all magnetic beads to be all adsorbed in after magnetic frame, transfer supernatant is in new test tube In.On
The PCR2 products after purifying are just contained in clear liquid.
(9) after library purifying terminates, Agilent 2100Bioanalyzer (Agilent companies of U.S. # are utilized G2939AA the purity and size in library) are detected, the kit used is that (U.S. Agilent is public by Agilent DNA 1000Kit Take charge of #5067-1504), testing result is as shown in figure 3, library size is in 768bp or so scope, and library purity is at a relatively high, And have not seen other non-specific amplification sequences.
(10) utilize2.0Fluorometer (U.S. Thermo Fisher Scientific company # Q32866), coordinateDsDNA HS Assay Kit kits (U.S. Thermo Fisher Scientific company # Q32851 DNA library concentration) is determined, and send company to carry out high-flux sequence.The cDNA library of gained is passed through into IlluminaPlatform (Illumina companies of the U.S.) is sequenced, and sequencing pattern is PE300, and library denaturant concentration is 2nM, and upper machine is dense Spend for 20pM, and pass through bioinformatic analysis high-flux sequence result.
Material and reagent explanation
Healthy volunteer's informed consent.No special illustrates that the reagent that the present invention is used is commercial goods, the present invention The database that embodiment is used is disclosed online database.
Specifically, the termination of reverse transcription 5 ' header sequence of the present invention, primer sequence are following (5 ' -3 '):
Reverse transcription step
The Oligo of XCR 3 ' (dT) primer:
5’TTTTTTTTTTTTTTTTTTTTGA 3’
The Oligo joints of XCR 5 ':
5’ATGCATCGGATCTTCAGCATGAACTTrGrGrG 3’
PCR1 steps
The end connector primers of XCR 5 ':
5’GTCTCGTGGGCTGGGCGATGTGTATGAGAGACAGCATGCATCGGATCTTCAGCATGA 3’
TCR-alpha chain C areas primer:
5’TCGTCGCCAGCGTCGGAAGTGTATAAGAGACAGTCTCAGCTGGTACATATCGATGTCAGGGT 3’
TCR-beta chain C areas primer:
5’TCGTCGCCAGCGTCGGAAGTGTATAAGAGACAGTCGCAGCGTCAGATGTGTATAAGAGACAG 3’
BCR-Heavy chain C areas primer:
IgA:
5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTAGGCTCCTGGGTTCCGAAGCC 3’
IgG:
5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTAGCGCCTGAGAAGGACGACAC 3’
IgM:
5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTAGGGGAATTCTTCTGGGAGAC 3’
BCR-Light chain C areas primer:
Kappa:
5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTACCTTCCACTCTATATTGGCCTC 3’
Lambda:
5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTAGCCACTGTATCCGCTCCCGGG 3’。
PCR2 steps
Label sense primer:
5’CAAGCAGAAGACGGCATACGAGAT[index1]GTCTCGTGGGCTGG 3’
Label TCR anti-sense primers:
5’AATGATACGGCGACCACCGAGATCTACAC[index2]TCGTCGCCAGCGTC 3’
Label B CR anti-sense primers:
5’AATGATACGGCGACCACCGAGATCTACAC[index3]TACGCGATATCGCT 3’
RG=RNA nucleotides
In Tag primerUnderscoreSequence label is sequenced for Illumina in part, and [] interior sequence is replaced by following table sequence, During for detecting multiple samples simultaneously, different index1-index2 or index1-index3 combinations and biological information are utilized Learn φt cell receptor (TCR) and B-cell receptor (BCR) sequencing result that algorithm distinguishes multiple samples.
Design of primers:Joint sequence and TCR during for RNA reverse transcriptions in 5 ' end additions are divided in BCR C areas gene Analysis, is analyzed primer dimer and stem ring mispairing using Oligo 7.36 and Primer Premier 6.0, at 5 ' ends Manual splice is provided with sense primer, and reverse primer is designed for C downstream of gene, and amplification TCR transcribes subregion sequence with BCR total lengths Row, wherein containing TCR and BCR immune groups storehouse FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 regions.
After the end connectors of PBMC RNA 5 ', primer and library construction using the present invention, high-flux sequence obtains about several Million TCR and BCR sequences.
Sequencing result carries out bioinformatic analysis, and (analysis of biological information uses Bowtie 2aligner (Ver.2.1.0), TCR and BCR derive from international immunogene information system according to storehouse matching www.imgt.org), Partial analysis comparison result is as shown in Figure 4,5.
By bioinformatic analysis, the information of every TCR and BCR sequence, amino acid information, bar can be accurately known Number and proportion.It is representative present invention obtains high-flux sequence sequence TCR and BCR by TCR and BCR comparative analyses The statistic analysis result of clone, as a result as shown in Fig. 4 (TCR) and 5 (BCR).
The above results show that TCR and BCR genes can be covered by building TCR and BCR libraries simultaneously using the method for the present invention Diversity information, improve the recall rate of low copy number immune cell clones and save time, reagent and cost of labor.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention Any modifications, equivalent substitutions and improvements made within refreshing and principle etc., should be included in the scope of the protection.
Sequence table SEQ UENCE LISTING
<110>Sun Tao
<120>It is a kind of to detect T cell and the primer combination in B cell immune group storehouse and kit simultaneously applied to high-flux sequence
<160> 34
<170> PatentIn version 3.3
<210> 1
<211> 22
<212> DNA
<213>It is artificial synthesized
<220>
<223>The Oligo of XCR 3 ' (dT) primer
<400> 1
ttttttttttttttttttttga 22
<210> 2
<211> 32
<212> DNA
<213>It is artificial synthesized
<220>
<223>The Oligo joints of XCR 5 '
<400> 2
atgcatcggatcttcagcatgaacttrgrgrg 32
<210> 3
<211> 57
<212> DNA
<213>It is artificial synthesized
<220>
<223>The end connector primers of XCR 5 '
<400> 3
gtctcgtgggctgggcgatgtgtatgagagacagcatgcatcggatcttcagcatga 57
<210> 4
<211> 62
<212> DNA
<213>It is artificial synthesized
<220>
<223>TCR-alpha chain C areas primer
<400> 4
tcgtcgccagcgtcggaagtgtataagagacagtctcagctggtacatatcgatgtcagggt 62
<210> 5
<211> 62
<212> DNA
<213>It is artificial synthesized
<220>
<223>TCR-beta chain C areas primer
<400> 5
tcgtcgccagcgtcggaagtgtataagagacagtcgcagcgtcagatgtgtataagagacag 62
<210> 6
<211> 55
<212> DNA
<213>It is artificial synthesized
<220>
<223>BCR-Heavy chain C area primer-IgA
<400> 6
tacgcgatatcgctctgcgctaactagtcgtactaggctcctgggttccgaagcc 55
<210> 7
<211> 55
<212> DNA
<213>It is artificial synthesized
<220>
<223> IgG
<400> 7
tacgcgatatcgctctgcgctaactagtcgtactagcgcctgagaaggacgacac 55
<210> 8
<211> 55
<212> DNA
<213>It is artificial synthesized
<220>
<223> IgM
<400> 8
tacgcgatatcgctctgcgctaactagtcgtactaggggaattcttctgggagac 55
<210> 9
<211> 57
<212> DNA
<213>It is artificial synthesized
<220>
<223>BCR-Light chain C area primer-Kappa
<400> 9
tacgcgatatcgctctgcgctaactagtcgtactaccttccactctatattggcctc 57
<210> 10
<211> 56
<212> DNA
<213>It is artificial synthesized
<220>
<223> Lambda
<400> 10
tacgcgatatcgctctgcgctaactagtcgtactagccactgtatccgctcccggg 56
<210> 11
<211> 46
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label sense primer
<400> 11
caagcagaagacggcatacgagatatctatcggtctcgtgggctgg 46
<210> 12
<211> 46
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label sense primer
<400> 12
caagcagaagacggcatacgagattcaggtgagtctcgtgggctgg 46
<210> 13
<211> 46
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label sense primer
<400> 13
caagcagaagacggcatacgagatcactagttgtctcgtgggctgg 46
<210> 14
<211> 46
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label sense primer
<400> 14
caagcagaagacggcatacgagatgaattgccgtctcgtgggctgg 46
<210> 15
<211> 46
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label sense primer
<400> 15
caagcagaagacggcatacgagat atgtacaagtctcgtgggctgg 46
<210> 16
<211> 46
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label sense primer
<400> 16
caagcagaagacggcatacgagatgattcagtgtctcgtgggctgg 46
<210> 17
<211> 46
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label sense primer
<400> 17
caagcagaagacggcatacgagatctgttcgtgtctcgtgggctgg 46
<210> 18
<211> 46
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label sense primer
<400> 18
caagcagaagacggcatacgagattatacggcgtctcgtgggctgg 46
<210> 19
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label TCR anti-sense primers
<400> 19
aatgatacggcgaccaccgagatctacactagctacttcgtcgccagcgtc 51
<210> 20
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label TCR anti-sense primers
<400> 20
aatgatacggcgaccaccgagatctacacattatagctcgtcgccagcgtc 51
<210> 21
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label TCR anti-sense primers
<400> 21
aatgatacggcgaccaccgagatctacaccccgtacttcgtcgccagcgtc 51
<210> 22
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label TCR anti-sense primers
<400> 22
aatgatacggcgaccaccgagatctacacgggtataatcgtcgccagcgtc 51
<210> 23
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label TCR anti-sense primers
<400> 23
aatgatacggcgaccaccgagatctacacagcaggtgtcgtcgccagcgtc 51
<210> 24
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label TCR anti-sense primers
<400> 24
aatgatacggcgaccaccgagatctacactatacgtatcgtcgccagcgtc 51
<210> 25
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label TCR anti-sense primers
<400> 25
aatgatacggcgaccaccgagatctacaccacctagttcgtcgccagcgtc 51
<210> 26
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label TCR anti-sense primers
<400> 26
aatgatacggcgaccaccgagatctacacgttgctactcgtcgccagcgtc 51
<210> 27
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label B CR anti-sense primers
<400> 27
aatgatacggcgaccaccgagatctacaccacgatgttacgcgatatcgct 51
<210> 28
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label B CR anti-sense primers
<400> 28
aatgatacggcgaccaccgagatctacactaatcgcttacgcgatatcgct 51
<210> 29
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label B CR anti-sense primers
<400> 29
aatgatacggcgaccaccgagatctacacatattacctacgcgatatcgct 51
<210> 30
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label B CR anti-sense primers
<400> 30
aatgatacggcgaccaccgagatctacaccctatacttacgcgatatcgct 51
<210> 31
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label B CR anti-sense primers
<400> 31
aatgatacggcgaccaccgagatctacac ggatgaaatacgcgatatcgct 51
<210> 32
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label B CR anti-sense primers
<400> 32
aatgatacggcgaccaccgagatctacacagtctttgtacgcgatatcgct 51
<210> 33
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label B CR anti-sense primers
<400> 33
aatgatacggcgaccaccgagatctacactagtggtatacgcgatatcgct 51
<210> 34
<211> 51
<212> DNA
<213>It is artificial synthesized
<220>
<223>Label B CR anti-sense primers
<400> 34
aatgatacggcgaccaccgagatctacacgtatgaactacgcgatatcgct 51

Claims (6)

1. a kind of primer combination for detecting T cell and B cell immune group storehouse simultaneously applied to high-flux sequence, it is characterised in that: The primer combination includes the Oligo of XCR 3 ' (dT) primer, the Oligo joints of XCR 5 ', the end connector primers of XCR 5 ', TCR- IgA, IgG and IgM in alpha chain C areas primer, TCR-beta chain C areas primer, BCR-Heavy chain C areas primer, BCR-Light Kappa and Lambda in chain C areas primer, and label upstream and downstream primer;Every kind of primer sequence is as follows:
The Oligo of XCR 3 ' (dT) primer:5’TTTTTTTTTTTTTTTTTTTTGA 3’;
The Oligo joints of XCR 5 ':5’ATGCATCGGATCTTCAGCATGAACTTrGrGrG 3’;
The end connector primers of XCR 5 ':
5’GTCTCGTGGGCTGGGCGATGTGTATGAGAGACAGCATGCATCGGATCTTCAGCATGA 3’;
TCR-alpha chain C areas primer:
5’TCGTCGCCAGCGTCGGAAGTGTATAAGAGACAGTCTCAGCTGGTACATATCGATGTCAGGGT 3’;
TCR-beta chain C areas primer:
5’TCGTCGCCAGCGTCGGAAGTGTATAAGAGACAGTCGCAGCGTCAGATGTGTATAAGAGACAG 3’;
BCR-Heavy chain C areas primer:
IgA:5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTAGGCTCCTGGGTTCCGAAGCC 3’;
IgG:5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTAGCGCCTGAGAAGGACGACAC 3’;
IgM:5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTAGGGGAATTCTTCTGGGAGAC 3’;
BCR-Light chain C areas primer:
Kappa:
5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTACCTTCCACTCTATATTGGCCTC 3’;
Lambda:
5’TACGCGATATCGCTCTGCGCTAACTAGTCGTACTAGCCACTGTATCCGCTCCCGGG 3’;
Label sense primer:5’CAAGCAGAAGACGGCATACGAGAT[index1]GTCTCGTGGGCTGG 3’;
Label TCR anti-sense primers:5’AATGATACGGCGACCACCGAGATCTACAC[index2]TCGTCGCCAGCGTC 3’;
Label B CR anti-sense primers:5’AATGATACGGCGACCACCGAGATCTACAC[index3]TACGCGATATCGCT 3’。
2. according to claim 2 a kind of drawing for T cell and B cell immune group storehouse is detected simultaneously applied to high-flux sequence Thing is combined, it is characterised in that:The index1 be ATCTATCG, TCAGGTGA, CACTAGTT, GAATTGCC, ATGTACAA, One kind in GATTCAGT, CTGTTCGT or TATACGGC;Index2 be TAGCTACT, ATTATAGC, CCCGTACT, One kind in GGGTATAA, AGCAGGTG, TATACGTA, CACCTAGT or GTTGCTAC;
Index3 be TAATCGCT, ATATTACC, CCTATACT, GGATGAAA, AGTCTTTG, TAGTGGTA, CACGATGT or One kind in GTATGAAC.
3. a kind of high-flux sequence that is applied to according to claim 1 or 2 detects T cell and B cell immune group storehouse simultaneously Kit, it is characterised in that:The kit includes primer combination as claimed in claim 1 or 2.
4. a kind of examination for detecting T cell and B cell immune group storehouse simultaneously applied to high-flux sequence according to claim 3 Agent box, it is characterised in that:The kit also includes PCR buffer solutions, Q5High-Fidelity 2X Master Mix, stoning Sour enzyme water, AMPure XP Beads and 70% ethanol.
5. a kind of examination for detecting T cell and B cell immune group storehouse simultaneously applied to high-flux sequence according to claim 4 Agent box, it is characterised in that:The kit includes:
(1) PCR buffer solutions:9.5μL;
(2) positive control RNA (1 μ g/ μ l):10μL;
(3) the 10 μM of Oligo of TCR 3 ' (dT) primers:1.1μL;
(4) 10 μM of end connector primers of TCR 5 ':2.2μL;
(5) 10 μM of TCR C area's primers and 10 μM of BCR C areas primers:Each 1.1 μ L;
(6)Q5High-Fidelity 2X Master Mix:55μL;
(9) 10 μM of label sense primers:2.2μL;
(10) 10 μM of TCR labels anti-sense primers and 10 μM of BCR label anti-sense primers:Each 1.1 μ L;
(11) nuclease water is removed:105μL;
(12)AMPure XP Beads:88μL;
(13) 70% ethanol:165μL.
6. one kind according to claim 4 or 5 is applied to high-flux sequence and detects T cell and B cell immune group storehouse simultaneously Kit, it is characterised in that:The PCR buffer solutions are made up of following system:
CN201611217595.1A 2016-12-26 2016-12-26 Primer combination and kit applied to high-throughput sequencing and simultaneous detection of T cell and B cell immune repertoire Active CN107058484B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611217595.1A CN107058484B (en) 2016-12-26 2016-12-26 Primer combination and kit applied to high-throughput sequencing and simultaneous detection of T cell and B cell immune repertoire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611217595.1A CN107058484B (en) 2016-12-26 2016-12-26 Primer combination and kit applied to high-throughput sequencing and simultaneous detection of T cell and B cell immune repertoire

Publications (2)

Publication Number Publication Date
CN107058484A true CN107058484A (en) 2017-08-18
CN107058484B CN107058484B (en) 2020-06-16

Family

ID=59624580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611217595.1A Active CN107058484B (en) 2016-12-26 2016-12-26 Primer combination and kit applied to high-throughput sequencing and simultaneous detection of T cell and B cell immune repertoire

Country Status (1)

Country Link
CN (1) CN107058484B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110938683A (en) * 2018-09-21 2020-03-31 深圳华大生命科学研究院 Method for evaluating library construction pollution degree of target area library and method for optimizing library construction
CN114480622A (en) * 2022-01-29 2022-05-13 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) Kit for predicting treatment sensitivity of psoriasis to methotrexate
CN117126921A (en) * 2023-10-26 2023-11-28 立凌生物制药(苏州)有限公司 Library construction method for detecting T cell and B cell immune repertoire, primer and kit thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008084405A2 (en) * 2007-01-11 2008-07-17 Erasmus University Medical Center Circular chromosome conformation capture (4c)
CN103710454A (en) * 2013-12-31 2014-04-09 南方科技大学 Method for TCR or BCR high-throughput sequencing and method for correcting multiple PCR primer deviation by using tag sequence
CN103987853A (en) * 2011-09-28 2014-08-13 Cb生物技术公司 Identification of antigen-specific adaptive immune responses using Arm-PCR and high-throughput sequencing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008084405A2 (en) * 2007-01-11 2008-07-17 Erasmus University Medical Center Circular chromosome conformation capture (4c)
CN103987853A (en) * 2011-09-28 2014-08-13 Cb生物技术公司 Identification of antigen-specific adaptive immune responses using Arm-PCR and high-throughput sequencing
CN103710454A (en) * 2013-12-31 2014-04-09 南方科技大学 Method for TCR or BCR high-throughput sequencing and method for correcting multiple PCR primer deviation by using tag sequence

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AARON C. LOGAN等: "Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival", 《BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION》 *
TAKARA: "SMARTer Human TCR a/b Profiling Kit", 《TAKARA》 *
WARREN EH等: "High-throughput sequencing of B- and T-lymphocyte antigen receptors in hematology", 《BLOOD》 *
余江等: "高通量测序分析自身免疫性疾病T细胞受体β链CDR3组库的特征", 《贵州医药》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110938683A (en) * 2018-09-21 2020-03-31 深圳华大生命科学研究院 Method for evaluating library construction pollution degree of target area library and method for optimizing library construction
CN114480622A (en) * 2022-01-29 2022-05-13 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) Kit for predicting treatment sensitivity of psoriasis to methotrexate
CN117126921A (en) * 2023-10-26 2023-11-28 立凌生物制药(苏州)有限公司 Library construction method for detecting T cell and B cell immune repertoire, primer and kit thereof
CN117126921B (en) * 2023-10-26 2024-01-26 立凌生物制药(苏州)有限公司 Library construction method for detecting T cell and B cell immune repertoire, primer and kit thereof

Also Published As

Publication number Publication date
CN107058484B (en) 2020-06-16

Similar Documents

Publication Publication Date Title
CN106755410A (en) A kind of method for detecting T cell and B cell immune group storehouse simultaneously based on high-flux sequence
US12129462B2 (en) Single cell bar-coding for antibody discovery
CN106498040B (en) A kind of molecular labeling microballon and the unicellular sequencing approach of high throughput based on the molecular labeling microballon
US8916504B2 (en) Methods of RNA display
CN109593758B (en) Multiplex primer set and method for constructing human B cell immune repertoire based on high-throughput sequencing by using same
CN108893464A (en) A kind of construction method of immune group library high-throughput sequencing library
TW201321518A (en) Method of micro-scale nucleic acid library construction and application thereof
CN109486923B (en) Primer system for sequencing multiple amplicons, application thereof and method for constructing sequencing library
CN106319639B (en) Build the method and apparatus of sequencing library
CN106283201B (en) The detection of TCR diversity and library construction based on high-flux sequence
CN107893068A (en) A kind of method for building people TCRbetaCDR3 areas library
CN103205420B (en) Primer composition for amplifying T cell receptor beta chain CDR3 coding sequence and application thereof
CN107779495B (en) Construction method and kit of T cell antigen receptor diversity sequencing library
CN105087560B (en) A kind of multiple PCR primer and method building pig BCR heavy chain library based on high-flux sequence
CN106957906A (en) A kind of primer combination and kit that T cell Minimal Residual Disease of Leukemia is detected applied to high-flux sequence
CN107058484A (en) It is a kind of to detect T cell and the primer combination in B cell immune group storehouse and kit simultaneously applied to high-flux sequence
EP3292217B1 (en) Formation of hairpins in situ using force-induced strand invasion
CN107747134A (en) A kind of method for building people TCRalphaCDR3 areas library
US20210054434A1 (en) Kit for amplifying immunoglobulin sequences
CN106957905A (en) A kind of molecular detecting method and Primer composition and kit for being used to assess immunotherapy of tumors effect
CN106978479A (en) A kind of method that T cell Minimal Residual Disease of Leukemia is detected based on high-flux sequence
CN109609611A (en) A kind of gene quantification sequencing approach based on high throughput sequencing technologies
CN107829145A (en) A kind of method for building mouse TCRalphaCDR3 areas library
CN107858400A (en) A kind of method for building mouse TCRbetaCDR3 areas library
CN113999891B (en) Methods, a set of primers and a kit for constructing an immune repertoire high throughput sequencing library that removes chimeric sequences in a sample

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200813

Address after: Room 103-8, building 7, Chuangzhi Green Valley Development Center, 788 HONGPU Road, Jianggan District, Hangzhou City, Zhejiang Province

Patentee after: HANGZHOU IMMUQUAD BIOTECHNOLOGIES, LLC

Address before: 610072 No. 1, unit 2, building 91, Daqing Road, Qingyang District, Sichuan, Chengdu, 10

Patentee before: Sun Tao